Drug Profile
Research programme: glaucoma therapy - Advanced Refractive Technologies
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator University of Arizona
- Developer Advanced Refractive Technologies
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Glaucoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Glaucoma in USA (Ophthalmic)
- 27 Sep 2006 Preclinical trials in Glaucoma in USA (Ophthalmic)